Compare ProShares Ultra Bitcoin ETF (BITU) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Bitcoin ETF vs Novartis AG — how do they compare? ProShares Ultra Bitcoin ETF trades at $9.69, while Novartis AG trades at $149.88 (market cap $288.65B). The key difference: Novartis AG pays a 3.15% dividend while ProShares Ultra Bitcoin ETF pays none, and Novartis AG is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BITU | NVS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $64.41 | $168.62 |
52-Week Low | $8.12 | $113.50 |
Market Cap | — | $288.65B |
Enterprise Value | — | $328.67B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITU trades at $9.01, down 5.16% over 24 hours amid bearish technical signals. The stock shows weak momentum with moving averages indicating a downtrend and oscillators neutral. Recent news highlights concerns over its leveraged ETF structure causing underperformance versus Bitcoin. The company pays small dividends but key valuation and profitability ratios are unavailable.
Outlook remains cautious due to structural decay risks and negative sentiment. Investment opportunity is limited to speculative traders during sustained bull markets, but risks of volatility decay and investor selling pressure outweigh potential gains in the near term.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra Bitcoin ETF
BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.
Read more on BITU →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
